Insider Selling: Repligen Co. (NASDAQ:RGEN) CEO Sells $3,377,314.72 in Stock

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anthony Hunt also recently made the following trade(s):

• On Friday, March 8th, Anthony Hunt sold 16,707 shares of Repligen stock. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08.

Repligen Stock Performance

RGEN stock opened at $158.16 on Friday. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The stock’s 50 day simple moving average is $173.40 and its 200 day simple moving average is $177.04. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.84 billion, a P/E ratio of 631.91, a P/E/G ratio of 5.52 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the firm posted $0.64 EPS. The company’s revenue was down 17.1% compared to the same quarter last year. As a group, equities research analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RGEN. Fifth Third Bancorp raised its holdings in shares of Repligen by 26.6% in the 3rd quarter. Fifth Third Bancorp now owns 2,258 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 474 shares in the last quarter. Teacher Retirement System of Texas raised its position in Repligen by 2.5% during the third quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 101 shares during the period. Daiwa Securities Group Inc. grew its position in Repligen by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after acquiring an additional 100 shares in the last quarter. WealthPlan Investment Management LLC acquired a new position in shares of Repligen during the 3rd quarter worth $210,000. Finally, Nisa Investment Advisors LLC grew its holdings in Repligen by 67.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 215 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on RGEN. JPMorgan Chase & Co. cut their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus upped their target price on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.